Applied Genetic Technologies (AGTC) PT Raised to $32 at Cantor Fitzgerald on Biogen Deal

Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating and boosted her price target on Applied Genetic Technologies Corp. (NASDAQ: AGTC) to $32.00 (from $28.00), saying the Biogen deal raises visibility and valuation.

commented, "are raising our PT on AGTC shares to $32 from $28 to reflect the impact of the Biogen collaboration, which includes an equity stake, cash and milestones, and fees, bringing the potential value of the deal (excluding future royalties) to greater than $1 billion."

For an analyst ratings summary and ratings history on Applied Genetic Technologies Corp. click here. For more ratings news on Applied Genetic Technologies Corp. click here.

Shares of Applied Genetic Technologies Corp. closed at $19.03 yesterday.

You May Also Be Interested In

• CACI International (CACI) PT Raised to $440 at Stifel
• Capitol Federal Financial (CFFN) PT Lowered to $5.50 at Piper Sandler
• Symrise AG (SY1:GR) (SYIEY) PT Raised to EUR120 at CFRA